Evaluation of 99Tcm-ECD as a white blood cell labelling agent

Nuclear Medicine Communications

Volumn 18, Issue 6, 1997, Pages 540-542

  Ozker, K ^a   Collier, B D ^a   Krasnow, A Z ^a   Hellman, R S ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M BICISATE; BUFFER; CYSTEINE ETHYL ESTER TC 99M; DRUG METABOLITE; PHOSPHATE; SODIUM CHLORIDE;

ARTICLE; BIOTRANSFORMATION; BRAIN; HUMAN; LEUKOCYTE; METABOLIC CLEARANCE RATE; SCINTISCANNING; VASCULARIZATION; BRAIN PERFUSION; CELL LABELING; CLINICAL PROTOCOL; CULTURE MEDIUM; DRUG PURITY; HUMAN CELL; ISOTOPE LABELING; LIPOPHILICITY; RADIOCHEMISTRY;

BIOTRANSFORMATION; BRAIN; CYSTEINE; HUMANS; LEUKOCYTES; METABOLIC CLEARANCE RATE; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS;

EID: 0030611244     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199706000-00007     Document Type: Article

References (31)

1. McAfee JG, Thakur ML. Survey of radioactive agents for in vivo labeling of phagocytic leukocytes. I. Soluble agents. J Nucl Med 1976; 17: 480-487.
2. Thakur ML, Lavender JP, Amot RN, Silvester DJ, Segal A. In-111 labeled autologous leukocytes in man. J Nucl Med 1977; 18: 1014-1021.
3. Thakur ML, McAfee JG. The significance of chromosomal aberrations in indium-lll-labeled lymphocytes. J Nucl Med 1984; 25: 922-927.
4. McAfee JG, Subramanian G, Gagne G, Schneider RF, Zapf-Longo C. Tc-99m-HMPAO for leukocyte labeling: Experimental comparison with In-111 oxine in dogs. Eur J Nucl Med 1987; 13: 353-357.
5. Schroth HI, Oberhausen E, Berberich R. Cell labeling with colloidal substances in whole blood. Eur J Nucl Med 1981; 6: 469-472.
6. Hanna R, Braun T, Levendel A, Lomas R Radiochemistry and biostability of autologous leukocytes labeled with Tc-99m-stannous colloid in whole blood. Eur J Nucl Med 1984; 5: 216-219.
7. Mock BH, English D. Leukocyte labeling with technetium-99m tin colloids. J Nucl Med 1987; 28: 1471-1477.
8. Linhart N, Bok B, Gougerot M, Gaillad MT, Meignan M. Tc-99m labeled human leukocytes: An in vitro functional study. Acta Haematol 1980; 63: 71-81.
9. Kelbaek H, Fogh J. Tc-99m labeled polymorphonuclear leukocytes: Preparation with two different stannous agents. J Nucl Med 1985; 26: 68-71.
10. Wistow BW, Grossman ZD, McAfee JG, Subramanian G, Henderson RW, Roskopf KML. Labeling of platelets with oxine complexes of Tc-99m and In-111. I. In vitro studies and survival in the rabbit. J Nucl Med 1978; 19: 483-487.
11. Segal GM, Lang EV, Chaovapong W. In vitro evaluation of white blood cell labeling with Tc-99m radiopharmaceuticals. Nucl Med Commun 1994; 15: 845-849.
12. Peters AM, Danapure HJ, Osman S et al. Clinical experience with Tc-99m hexamethylpropylene amine oxime for labeling leukocytes and imaging inflammation. Lancet 1986; 2: 946-949.
13. Neirinckx RD, Canning LR, Piper IM et al. Technetium 99m-d, HMPAO: A new radiopharmaceutical for SPECT imaging of regional cerebral perfusion. J Nucl Med 1987; 28: 191-202.
14. Hung JC, Corlija M, Volkert WA, Holmes RA. Kinetic analysis of technetium-99m-d, f-HMPAO decomposition in aqueous media. J Nucl Med 1988; 291: 568-576.
15. Ramamoorty N, Pillai MRA, Troutner DE. Studies on some aspects of the instability of Tc-hexamethylpropylene amine oxime (Tc-HMPAO). Nucl Med Biol 1993; 20: 307-310.
16. Millar AM. Routine method for using sodium iodide to stabilize sodium pertechnetate (Tc-99m) dispensed for the preparation of Tc-99m-exametazime. Nucl Med Commun 1992; 13: 306-311.
17. Hung JC, Volkert WA, Holmes RA. Stabilization of techne-tium-99m-D, L-hexamethylpropylene amine oxime (Tc-99m-d, l-HMPAO) using gentisic acid. Nucl Med Biol 1989; 16: 675-680.
18. Pierra C, Pavia A, Bassa P, Garcia J. Preparation of Tc-99m-HMPAO (letter). J Nucl Med 1990; 31: 127-128.
19. Ballinger J. Preparation of Tc-99m-HMPAO Getter). J Nucl Med 1990; 31: 1892.
20. Hawkins T, Reeder A, Keavey PM, Thakker S, Hawker R. The long term stability of reconstituted exametazime: A clinical and laboratory evaluation. Nucl Med Commun 1991; 12: 1045-1055.
21. Ballinger JR, Gulenchyn KY, Reid RH. Radiopharmaceutical factors in variable quality of Tc-99m HMPAO images of the brain. J Nucl Med 1990; 31: 118-122.
22. Morrissey GJ, Powe JE. Routine application of fractionated HMPAO stored at-70°C for WBC scintigraphy. J Nucl Med 1993; 34: 151-155.
23. Ceretec for white blood cell imaging: User’s guide, Amersham Healthcare, 1995.
24. Neurolite package insert. DuPont Merck Pharmaceutical Company, 1994.
25. Walovitch RC, Hill TC, Garrity ST et al. Characterization of Tc-99m-L, L-ECD for brain perfusion imaging. Part I: Pharmacology of Tc-99m ECD in nonhuman primates. J Nucl Med 1989; 30: 1892-1901.
26. Leveille, Demoneau G, DeRoo M et al. Characterization of Tc-99m-L, L-ECD for brain perfusion imaging. Part II: Biodistribution and brain imaging in humans. J Nucl Med 1989; 30: 1902-1910.
27. Walovitch RC, Cheesman EH, Maheu LJ, Hall KM. Studies of the retention mechanism of the brain perfusion imaging agent Tc-99m-bicisate (Tc-99m ECD). J Cereb Blood Flow Metab 1994; 14: S4-S11.
28. Wallabhajosula S, Zimmerman RE, Picard M et al. Techne-tium-99m ECD A new brain imaging agent. In vivo kinetics and biodistribution studies in normal human subjects. J Nucl Med 1989; 30: 599-604.
29. Walovitch RC, Franceshi M, Picard M et al. Metabolism of Tc-99m-L, L-ethyl cysteinate dimer in healthy volunteers. Neuropharmacology 1991; 30: 283-292.
30. Inoue Y, Momose T, Amo K et al. Metabolism of Tc-99m ethyl cysteinate dimer (Tc-99m ECD) in blood mainly in vitro. Jap J Nucl Med 1992; 29: 955-962.
31. Kao CH, Huang WT, Wang YL et al. A comparative study of Tc-99m HMPAO and Tc-99m ECD as a leukocyte labeling agent. Nucl Med Commun 1994; 15: 294-297.